Response outcomes of epcoritamab vs comparators. Unadjusted and adjusted ORR and CR rates with ORs (95% CI) for (A) epcoritamab vs SOC/CIT; (B) epcoritamab vs mosunetuzumab; and (C) epcoritamab vs odronextamab.
Figure 1.

Response outcomes of epcoritamab vs comparators. Unadjusted and adjusted ORR and CR rates with ORs (95% CI) for (A) epcoritamab vs SOC/CIT; (B) epcoritamab vs mosunetuzumab; and (C) epcoritamab vs odronextamab.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal